Navigation Links
New Stem Cell Web Site to Focus on Traumatic Brain Injury, Spinal Cord Injury and Diabetes
Date:5/28/2009

SAN DIEGO, May 28 /PRNewswire/ -- Entest BioMedical, Inc., a newly formed wholly-owned subsidiary of San Diego-based Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN) announced today the launch of its Web site (http://www.EntestBio.com) to focus on new stem cell research, including a proposed research to develop a new therapeutic solution for traumatic brain injury (TBI) using autologous adipose-derived (fat) stem cells representing a potential cure. There are currently 1.5 million new cases of TBI occurring in the U.S. each year, adding to the almost 6.5 million existing cases. The Company is also pursuing research in the use of fat stem cell therapy for spinal cord injury, in which approximately 200,000 patients in the U.S. suffer from this disability.

The site also highlights the Company's progress in developing a gestational diabetes screening test, as the exclusive licensee granted by UCLA. The non-invasive, highly accurate streamline test mitigates the lengthy process of diagnoses and would more quickly treat the glucose intolerant disease, which potentially impacts 4.3 million pregnant women each year.

Along with background about types of stem cells and factoids, the new site also reviews Entest BioMedical's focus on the promising field of in vitro expansion of adult stem cells using other types of cells, such as peripheral stem cells and cord blood stem cells to treat cancer and other diseases. The R & D company is also exploring isolating hematopoietic stem cells from peripheral blood or bone marrow and differentiating them into immune cells, especially T cells.

"Our new Web site demonstrates Entest BioMedical's mission and key scientific personnel who are dedicated to discovering and developing new procedures, treatments and medical devices that improve the quality of life - leading research and technology that serve the present and help shape the future," said David Koos, Ph.D., DBA, Chairman and CEO.

About Entest BioMedical, Inc.

Entest BioMedical, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTC BB: BMSN) formed in April 2009, focuses on research and development of traumatic brain injury (TBI) and spinal cord injury using autologous "adipose-derived" stem cells. Entest BioMedical is involved with R&D activities relating to stem cell therapies, diabetes testing and medical devices.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


'/>"/>
SOURCE Entest BioMedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion
2. Nfocus Neuromedical Appoints Robert OHolla to Head Regulatory
3. Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail
4. Cellectricon and BioFocus DPI Advance High Throughput ion Channel Drug Discovery
5. Health Strategies Group Expands Focus of Pharma Sales Force Effectiveness Service Under New Vision and Name
6. Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence
7. Jivan Focuses on Solutions for Transcriptome Sequencing
8. ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
9. Siemens Focuses on Role-Based, Context-Sensitive, and Knowledge-Driven Solutions at HIMSS 2009
10. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
11. Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake Lubinski, describes ... characteristics when deformed, which is identical to how the human discs work to ... and return to its natural state along a hysteresis curve, exactly like a ...
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... York , March 23, 2017 According ... plasma products and derivatives market is fragmented due to the presence of ... such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with ... these three companies, collectively, held more than 76% of this market ... As ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers face a ... lab samples to full-size tissues, bones, even whole organs to implant in people ... delivers blood deep into the developing tissue. , Current bioengineering techniques, including ...
Breaking Biology Technology:
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):